{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:01:55Z","timestamp":1788843715907,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Dried blood spot (DBS) sampling is a convenient alternative to whole-blood sampling for therapeutic drug monitoring (TDM) in clinical practice. The aim of this study was to systematically review studies that have examined and used DBS sampling for the TDM of chemotherapy and targeted therapy agents for the treatment of patients with solid cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Using the PRISMA guidelines, a systematic literature search of EMBASE and PUBMED was performed to identify eligible clinical studies that used DBS sampling to monitor chemotherapy or targeted therapy for the treatment of solid cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 23 eligible studies, 3 measured concordance between drug concentrations determined by DBS and whole-blood, 7 developed analytical methods of DBS, and 13 performed both. DBS was employed for the TDM of everolimus (3 studies), vemurafenib (2 studies), pazopanib (2 studies), abiraterone (2 studies), mitotane, imatinib, adavosertib, capecitabine, 5-fluorouracil, gemcitabine, cyclophosphamide, ifosfamide, etoposide, irinotecan, docetaxel, gefitinib, palbociclib\/ribociclib, and paclitaxel (one study each). The studies included a median of 14 participants (range: 6\u201334), with 10\u201350 \u03bcL of blood dispensed on DBS cards (20) and Mitra devices (3). Seventeen of the 20 studies that used DBS found no significant impact of the hematocrit on the accuracy and precision of the developed method in the normal hematocrit ranges (eg, 29.0%\u201359.0%). DBS and plasma or venous concentrations were highly correlated (correlation coefficient, 0.872\u20130.999) for all drugs, except mitotane, which did not meet a predefined level of significance (r &gt; 0.872; correlation coefficient, r = 0.87, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>DBS provides an alternative sampling strategy for the TDM of many anticancer drugs. Further research is required to establish a standardized approach for sampling and processing DBS samples to allow future implementation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001082","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T04:00:27Z","timestamp":1675828827000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review"],"prefix":"10.1097","volume":"45","author":[{"given":"Mohsen","family":"Shafiei","sequence":"first","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health, University of Sydney ;"},{"name":"Concord Cancer Centre, Concord Repatriation General Hospital, NSW, 2139 ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Concord Cancer Centre, Concord Repatriation General Hospital, NSW, 2139 ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beale","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health, University of Sydney ;"},{"name":"Concord Cancer Centre, Concord Repatriation General Hospital, NSW, 2139 ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[{"name":"Centre for Drug Repurposing and Medicines Research, University of Newcastle, Callaghan, NSW; and"},{"name":"Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Martin","sequence":"additional","affiliation":[{"name":"Centre for Drug Repurposing and Medicines Research, University of Newcastle, Callaghan, NSW; and"},{"name":"Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, University of Sydney ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prunella","family":"Blinman","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health, University of Sydney ;"},{"name":"Concord Cancer Centre, Concord Repatriation General Hospital, NSW, 2139 ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.21037\/tcr.2017.10.30","article-title":"Precision dosing of targeted anticancer drugs\u2014challenges in the real world","volume":"6","author":"Kim","year":"2017","journal-title":"Transl Cancer Res."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","article-title":"Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative","volume":"14","author":"Gurney","year":"1996","journal-title":"J Clin Oncol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.14372","article-title":"Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology","volume":"87","author":"Menz","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00280-016-3097-4","article-title":"Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations","volume":"78","author":"Mizoguchi","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors","volume":"34","author":"Teng","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1158\/1078-0432.CCR-17-1344","article-title":"Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: pharmacokinetic results of a phase II multicenter study","volume":"23","author":"Moeung","year":"2017","journal-title":"Clin Cancer Res."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00007691-199510000-00007","article-title":"Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions","volume":"17","author":"Pignon","year":"1995","journal-title":"Ther Drug Monit."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbmt.2007.09.015","article-title":"Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation","volume":"14","author":"Bartelink","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-11-0557","article-title":"High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up","volume":"166","author":"Mauclere-Denost","year":"2012","journal-title":"Eur J Endocrinol."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.14185","article-title":"Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose","volume":"86","author":"Westerdijk","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","article-title":"Review of therapeutic drug monitoring of anticancer drugs part 1-cytotoxics","volume":"50","author":"Paci","year":"2014","journal-title":"Eur J Cancer"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10544-019-0412-y","article-title":"A review of microsampling techniques and their social impact","volume":"21","author":"Lei","year":"2019","journal-title":"Biomed Microdevices"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12879-017-2776-z","article-title":"Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis","volume":"17","author":"Lange","year":"2017","journal-title":"BMC Infect Dis."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"e86461","DOI":"10.1371\/journal.pone.0086461","article-title":"Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis","volume":"9","author":"Smit","year":"2014","journal-title":"PLoS One"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/ijns6020026","article-title":"Use of dried blood spot specimens to monitor patients with inherited metabolic disorders","volume":"6","author":"Moat","year":"2020","journal-title":"Int J Neonatal Screen."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med."},{"key":"R19-20250603","first-page":"238","article-title":"Determination of capecitabine-an anticancer drug in dried blood spot by LC-ESI-MS\/MS","volume":"7","author":"Singhal","year":"2015","journal-title":"Int J Pharm Pharm Sci."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"123075","DOI":"10.1016\/j.jchromb.2021.123075","article-title":"Measurement of 5-fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS\/MS","volume":"1188","author":"Radovanovic","year":"2022","journal-title":"J Chromatogr B"},{"key":"R21-20250603","first-page":"75","article-title":"Development and validation of a dried blood spot LC-MS\/MS assay to quantify gemcitabine in human whole blood: a comparison with and without cytidine deaminase inhibitor","volume":"7","author":"Kumar","year":"2015","journal-title":"Int J Pharm Pharm Sci."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"119","DOI":"10.22159\/ijap.2020v12i4.36092","article-title":"Method development on analysis cyclophosphamide and 4-hydroxycyclophophamide in dried blood spot and its application in breast cancer patients","volume":"12","author":"Harahap","year":"2020","journal-title":"Int J Appl Pharm."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"e0143421","DOI":"10.1371\/journal.pone.0143421","article-title":"A new method to quantify ifosfamide blood levels using dried blood spots and UPLC-MS\/MS in paediatric patients with embryonic solid tumours","volume":"10","author":"Torres","year":"2015","journal-title":"PLoS One"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2015.10.026","article-title":"A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection","volume":"452","author":"Re\u017eonja Kukec","year":"2016","journal-title":"Clinica Chim Acta"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpba.2017.11.079","article-title":"Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection","volume":"150","author":"Hahn","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpba.2018.05.011","article-title":"Determination of docetaxel in dried blood spots by LC-MS\/MS: method development, validation and clinical application","volume":"157","author":"Raymundo","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.clinbiochem.2018.02.020","article-title":"Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry","volume":"54","author":"Andriguetti","year":"2018","journal-title":"Clin Biochem."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s00216-019-01868-1","article-title":"A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring","volume":"411","author":"Friedl","year":"2019","journal-title":"Anal Bioanal Chem."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s00216-012-6440-6","article-title":"Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS\/MS in support of clinical studies","volume":"404","author":"Xu","year":"2012","journal-title":"Anal Bioanal Chem."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.4155\/bio.14.171","article-title":"Quantifying vemurafenib in dried blood spots using high-performance LC-MS\/MS","volume":"6","author":"Nijenhuis","year":"2014","journal-title":"Bioanalysis"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/jcph.728","article-title":"The use of dried blood spots for pharmacokinetic monitoring of vemurafenib treatment in melanoma patients","volume":"56","author":"Nijenhuis","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/bio.15.235","article-title":"Development and clinical validation of an LC-MS\/MS method for the quantification of pazopanib in DBS","volume":"8","author":"Verheijen","year":"2016","journal-title":"Bioanalysis"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jcph.558","article-title":"Dried blood spot analysis for therapeutic drug monitoring of pazopanib","volume":"55","author":"de Wit","year":"2015","journal-title":"J Clin Pharmacol."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jpba.2017.10.039","article-title":"Development and validation of an analytical method using UPLC-MS\/MS to quantify everolimus in dried blood spots in the oncology setting","volume":"149","author":"Knapen","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-017-2394-0","article-title":"Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer","volume":"74","author":"Willemsen","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2018.11.030","article-title":"Validation and clinical application of an LC-MS\/MS method for the quantification of everolimus using volumetric absorptive microsampling","volume":"1104","author":"Verheijen","year":"2019","journal-title":"J Chromatogr B"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2018.04.027","article-title":"Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: application to finger-prick clinical blood samples of patients with non-small cell lung cancer","volume":"1087-1088","author":"Irie","year":"2018","journal-title":"J Chromatogr B"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"e0225225","DOI":"10.1371\/journal.pone.0225225","article-title":"Development and validation of LC-MS\/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients","volume":"14","author":"Iacuzzi","year":"2019","journal-title":"PLoS One"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"121741","DOI":"10.1016\/j.jchromb.2019.121741","article-title":"Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and \u2206(4)-abiraterone from cancer patients","volume":"1126-1127","author":"Bhatnagar","year":"2019","journal-title":"J Chromatogr B"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"113861","DOI":"10.1016\/j.jpba.2020.113861","article-title":"Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients","volume":"195","author":"Dillenburg Weiss","year":"2021","journal-title":"J Pharm Biomed Anal."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"122985","DOI":"10.1016\/j.jchromb.2021.122985","article-title":"A new dried blood spot LC-MS\/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer","volume":"1185","author":"Poetto","year":"2021","journal-title":"J Chromatogr B"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/pgs.13.33","article-title":"Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy","volume":"14","author":"Krens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF03261934","article-title":"Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study","volume":"51","author":"Joerger","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed Chromatogr."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11095-021-03036-6","article-title":"Dried blood spot technique applied in therapeutic drug monitoring of anticancer drugs: a review on conversion methods to correlate plasma and dried blood spot concentrations","volume":"38","author":"Iacuzzi","year":"2021","journal-title":"Pharm Res."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.4155\/bio.10.103","article-title":"The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs","volume":"2","author":"Denniff","year":"2010","journal-title":"Bioanalysis"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4155\/bio.13.171","article-title":"In-depth study of homogeneity in DBS using two different techniques: results from the EBF DBS microsampling consortium","volume":"5","author":"Cobb","year":"2013","journal-title":"Bioanalysis"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1021\/ac5022562","article-title":"Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis","volume":"86","author":"Denniff","year":"2014","journal-title":"Anal Chem."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.aca.2015.04.056","article-title":"Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study","volume":"881","author":"De Kesel","year":"2015","journal-title":"Analytica Chim Acta"},{"key":"R52-20250603","first-page":"140","article-title":"Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation","volume":"21","author":"Cheung","year":"2008","journal-title":"Transpl Int."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3851\/IMP2501","article-title":"Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study","volume":"18","author":"Kromdijk","year":"2012","journal-title":"Antivir Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:10:14Z","timestamp":1748970614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001082","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"2022-06-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}